We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Chemed (CHE) Stock for Now
Read MoreHide Full Article
Chemed Corporation (CHE - Free Report) has been gaining from strength in both VITAS and Roto-Rooter segments. Sequential growth in hospital-directed admissions and nursing home admissions within the VITAS arm appears promising. Furthermore, a good solvency position buoys optimism for the stock. Yet, pandemic-led disruptions and seasonality of the business raise apprehension.
Over the past six months, the Zacks Rank #3 (Hold) stock has gained 1.2% against a 25.1% decline of the industry and a 7.7% rise of the S&P 500.
The renowned hospice care provider has a market capitalization of $7.37 billion. Chemed’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 5.6%.
Over the past five years, Chemed’s earnings grew 22.2%, way ahead of the industry and S&P 500’s 17.3% and 2.8% increase, respectively. The company projects 7.7% growth for the next five years compared with the industry and the S&P 500’s projected growth rate of 20.2% and 11.9%, respectively.
Image Source: Zacks Investment Research
Let’s delve deeper.
Factors at Play
VITAS Prospects Bright: Chemed’s VITAS segment has been registering robust performance over the last few quarters. Total VITAS admissions in the third quarter came at 17,598, registering a 4.5% increase from the second quarter. The company also saw a 2% increase in hospital-directed admissions, a 16.3% rise in total home-based pre-admit admissions, an 8.9% spike in nursing home admissions and a 5% increase in assisted living facility admissions, on a sequential basis. Chemed’s updated guidance suggests a sequential improvement in senior housing base patients in the fourth quarter and acceleration in senior housing admissions in 2022, further raising optimism surrounding the stock.
Roto-Rooter Continues to Expand: We are upbeat about Chemed’s Roto-Rooter segment, which is currently the leading provider of plumbing, drain cleaning service and water restoration in the United States. On a year-over-year basis, Roto-Rooter’s revenues rose 15.7% for the third quarter. Total branch commercial revenues improved 10% while Roto-Rooter branch residential revenues registered 17.2% growth for the reported quarter. Management believes Roto-Rooter is well positioned for post-pandemic growth and anticipates continued expansion of the segment’s market share.
Strong Solvency: Chemed exited the third quarter with cash and cash equivalents of $28.7 million and no long-term debt. This is suggestive of the fact that Chemed’s solvency level is pretty promising.
Downsides
Pandemic Causes Revenue Erosion: The COVID-19 pandemic continues to impact senior housing occupancy, according to data released by the National Investment Center for Seniors Housing & Care. In this regard, pandemic-led disruptions to senior housing occupancy and hospice referrals continued to challenge Chemed's VITAS segment in the third quarter.
Seasonality Headwinds: A substantial portion of VITAS admissions and revenues are concentrated only within the state of Florida, as retirees often tend to relocate to the state during winter months. Further, Roto-Rooter’s revenues and operating results are impacted by weather patterns across the United States.
Tough Competition: Chemed faces significant competition in the sewer, drain and pipe cleaning, and plumbing repair markets. The VITAS arm also competes with a large number of organizations on the basis of its ability to deliver quality, responsive services.
Estimate Trend
Over the past 90 days, the Zacks Consensus Estimate for Chemed’s 2021 earnings has moved 4.2% north to $19.14.
The Zacks Consensus Estimate for the company’s 2021 revenues is pegged at $2.14 billion, suggesting a 3.0% rise from the 2020 reported number.
Key Picks
Some better-ranked stocks in the broader medical space include Baxter International Inc. (BAX - Free Report) , Hologic, Inc. (HOLX - Free Report) and Apollo Endosurgery, Inc. .
Baxter, currently carrying a Zacks Rank #1 (Strong Buy), has a long-term earnings growth rate of 9.5%. Baxter’s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 10.2%, on average. You can see the complete list of today’s Zacks #1 Rank stocks here.
Baxter has outperformed the industry over the past year. BAX has gained 7.9% against a 12.8% decline of the industry in the said period.
Hologic, holding a Zacks Rank #1 at present, has a long-term earnings growth rate of 7.4%. The company surpassed earnings estimates in three of the trailing four quarters and missed on another occasion, delivering an average surprise of 29.2%.
Hologic has declined 10.1%, underperforming the industry’s 8.1% drop over the past year.
Apollo Endosurgery, presently carrying a Zacks Rank #2 (Buy), has a long-term earnings growth rate of 7%. Apollo Endosurgery’s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 25.6%, on average.
Apollo Endosurgery has outperformed the industry in the past year. APEN has gained 43.5% versus the industry’s 8.1% fall in the said period.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Retain Chemed (CHE) Stock for Now
Chemed Corporation (CHE - Free Report) has been gaining from strength in both VITAS and Roto-Rooter segments. Sequential growth in hospital-directed admissions and nursing home admissions within the VITAS arm appears promising. Furthermore, a good solvency position buoys optimism for the stock. Yet, pandemic-led disruptions and seasonality of the business raise apprehension.
Over the past six months, the Zacks Rank #3 (Hold) stock has gained 1.2% against a 25.1% decline of the industry and a 7.7% rise of the S&P 500.
The renowned hospice care provider has a market capitalization of $7.37 billion. Chemed’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 5.6%.
Over the past five years, Chemed’s earnings grew 22.2%, way ahead of the industry and S&P 500’s 17.3% and 2.8% increase, respectively. The company projects 7.7% growth for the next five years compared with the industry and the S&P 500’s projected growth rate of 20.2% and 11.9%, respectively.
Let’s delve deeper.
Factors at Play
VITAS Prospects Bright: Chemed’s VITAS segment has been registering robust performance over the last few quarters. Total VITAS admissions in the third quarter came at 17,598, registering a 4.5% increase from the second quarter. The company also saw a 2% increase in hospital-directed admissions, a 16.3% rise in total home-based pre-admit admissions, an 8.9% spike in nursing home admissions and a 5% increase in assisted living facility admissions, on a sequential basis. Chemed’s updated guidance suggests a sequential improvement in senior housing base patients in the fourth quarter and acceleration in senior housing admissions in 2022, further raising optimism surrounding the stock.
Roto-Rooter Continues to Expand: We are upbeat about Chemed’s Roto-Rooter segment, which is currently the leading provider of plumbing, drain cleaning service and water restoration in the United States. On a year-over-year basis, Roto-Rooter’s revenues rose 15.7% for the third quarter. Total branch commercial revenues improved 10% while Roto-Rooter branch residential revenues registered 17.2% growth for the reported quarter. Management believes Roto-Rooter is well positioned for post-pandemic growth and anticipates continued expansion of the segment’s market share.
Strong Solvency: Chemed exited the third quarter with cash and cash equivalents of $28.7 million and no long-term debt. This is suggestive of the fact that Chemed’s solvency level is pretty promising.
Downsides
Pandemic Causes Revenue Erosion: The COVID-19 pandemic continues to impact senior housing occupancy, according to data released by the National Investment Center for Seniors Housing & Care. In this regard, pandemic-led disruptions to senior housing occupancy and hospice referrals continued to challenge Chemed's VITAS segment in the third quarter.
Seasonality Headwinds: A substantial portion of VITAS admissions and revenues are concentrated only within the state of Florida, as retirees often tend to relocate to the state during winter months. Further, Roto-Rooter’s revenues and operating results are impacted by weather patterns across the United States.
Tough Competition: Chemed faces significant competition in the sewer, drain and pipe cleaning, and plumbing repair markets. The VITAS arm also competes with a large number of organizations on the basis of its ability to deliver quality, responsive services.
Estimate Trend
Over the past 90 days, the Zacks Consensus Estimate for Chemed’s 2021 earnings has moved 4.2% north to $19.14.
The Zacks Consensus Estimate for the company’s 2021 revenues is pegged at $2.14 billion, suggesting a 3.0% rise from the 2020 reported number.
Key Picks
Some better-ranked stocks in the broader medical space include Baxter International Inc. (BAX - Free Report) , Hologic, Inc. (HOLX - Free Report) and Apollo Endosurgery, Inc. .
Baxter, currently carrying a Zacks Rank #1 (Strong Buy), has a long-term earnings growth rate of 9.5%. Baxter’s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 10.2%, on average. You can see the complete list of today’s Zacks #1 Rank stocks here.
Baxter has outperformed the industry over the past year. BAX has gained 7.9% against a 12.8% decline of the industry in the said period.
Hologic, holding a Zacks Rank #1 at present, has a long-term earnings growth rate of 7.4%. The company surpassed earnings estimates in three of the trailing four quarters and missed on another occasion, delivering an average surprise of 29.2%.
Hologic has declined 10.1%, underperforming the industry’s 8.1% drop over the past year.
Apollo Endosurgery, presently carrying a Zacks Rank #2 (Buy), has a long-term earnings growth rate of 7%. Apollo Endosurgery’s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 25.6%, on average.
Apollo Endosurgery has outperformed the industry in the past year. APEN has gained 43.5% versus the industry’s 8.1% fall in the said period.